|
|
|
Impact factor: 0.576
|
|
|
|
|
|
ISSN: 1521-9437 Print
ISSN: 1940-4344 Online
|
|
|
|
| |
You can order a single issue or an individual article, as well as view the table of contents or article abstract by clicking on the volume number, then the issue number in the right sidebar.
|
|
|
|
|
|
Institutional price: $610.00
|
|
Online subscription
|
|
DOI: 10.1615/IntJMedMushr.v7.i4
Pages: 102
|
DOI: 10.1615/IntJMedMushr.v7.i4.30
|
Article price - $35.00 |
 |
Antitumor Effect of Combination Therapy of Proflamin with Cryosurgery of Meth-A Fibrosarcoma in BALB/c Mice
Hirofumi Maruyama
Japanese Association for Integrative Medicine, Kandakonya-cho, Tokyo, Japan
Tetsuro Ikekawa
Japanese Association of Integrative Medicine (JAIM). Association for Popularization of Integrative Medicine and Treatments (NPO, Japan), Sanshin Building, 3F, 2-15-14 Uchikanda, Chiyoda-ku, Tokyo 101-0047,Japan
ABSTRACT
Proflamin (PRF), an antitumor agent, is orally effective against the syngeneic tumors in mice and is a new biological response modifier, which was isolated from the culture mycelium of Flammulina velutipes (W. Curt.: Fr.) Singer. Cryosurgery was used against tumors in this study in which cryoimmune effects were revealed. In this study, immunomodulation with PRF administration was evaluated in combination with cryosurgery. Cryosurgery was carried out on Meth-A fibrosarcoma 7 days after the inoculation of tumor cells into BALB/c mice. The tumor-bearing mice were found to have acquired tumor immunocompetence against the Meth-A tumors after receiving cryosurgery. This tumor immunocompetence reached nadir 2 weeks after the cryosurgery and increased gradually thereafter, reaching its maximum level at 5 weeks and remaining there for 7 weeks. Therapy in combination with cryosurgery and the immunopotentiator PRF was found to abolish the depression of tumor immunocompetence 2 weeks after cryosurgery. PRF was found to augment tumor immunity caused after cryosurgery, and thus it is coincident with modulation. The combination of cryosurgery and an immunopotentiator is suggested to be effective for maintaining the immunocompetence at a high level for a long duration and may be a useful tool in treating cancer.
pages 539-546
|
|
Volume 11, 2009 Volume 10, 2008 Volume 9, 2007 Volume 8, 2006 Volume 7, 2005 Volume 6, 2004 Volume 5, 2003 Volume 4, 2002 Volume 3, 2001 Volume 2, 2000
|
|
|
|
|
|